Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.60% | 21.75% | 39.07% | -8.17% | -97.75% |
| Total Depreciation and Amortization | -- | -92.86% | -93.33% | -93.75% | 250.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 939.94% | 4,174.36% | -65.72% | 631.02% | 112.33% |
| Change in Net Operating Assets | -106.18% | -78.44% | -18.30% | 325.33% | 855.08% |
| Cash from Operations | 15.81% | 34.95% | 42.90% | 31.66% | 23.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 109.90% | 110.11% | -100.00% | -- | -- |
| Total Debt Repaid | 43.29% | -115.76% | -273.08% | -901.86% | -- |
| Issuance of Common Stock | -9.97% | -26.76% | -26.76% | 132.36% | 70.20% |
| Repurchase of Common Stock | -- | -- | -10,600.00% | -10,600.00% | -10,600.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.87% | -22.56% | -43.53% | 118.09% | 56.52% |
| Foreign Exchange rate Adjustments | 125.00% | 100.00% | 450.00% | -50.00% | -157.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 319.56% | 111.99% | 53.20% | 112.97% | 87.39% |